⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
RDY News
Dr. Reddy's Laboratories Limited American Depositary Shares
Aurigene Oncology Limited annonce des données initiales encourageantes provenant des deux premiers groupes de l'étude de phase 1 évaluant l'AUR112, un inhibiteur oral à petites molécules de MALT1, pour les lymphopathies malignes...
businesswire.com
RDY
Aurigene Oncology Limited Announces Encouraging Initial Data From 1 st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies
businesswire.com
RDY